EXAGEN INC (XGN) Stock News
NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD
XGN Latest News, Press Relases and Analysis
Top movers in Thursday's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
Get insights into the top gainers and losers of Wednesday's after-hours session.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it...
Exagen Inc. Prices Public Offering of Common Stock
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the...
Exagen Inc. Announces Proposed Public Offering of Common Stock
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported...
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results...
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized...
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results...
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing...
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. Reports Third Quarter 2024 Results
Exagen Inc. Reports Third Quarter 2024 Results
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with...
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance...
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its...